ClinicalTrials.Veeva

Menu

hepatomiR cACLD Study

K

Karl Landsteiner University of Health Sciences

Status

Enrolling

Conditions

Portal Hypertension
Chronic Liver Disease
Chronic Liver Disease and Cirrhosis

Treatments

Diagnostic Test: hepatomiR

Study type

Observational

Funder types

Other

Identifiers

NCT06432582
UKStP_hepatomiR_cACLD

Details and patient eligibility

About

This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic encephalopathy) in chronic liver disease (CLD). Based on these data, it is aimed to advance the current understanding of factors driving decompensation, with potential repercussions for future risk management and therapy.

Enrollment

156 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 years
  • Chronic liver disease (more than 6 months)
  • LSM ≥ 10 kPa
  • Outpatient at the Clinical Department of Internal Medicine II, University Hospital St. Pölten
  • Signed patient consent form

Exclusion criteria

  • Age older than 18 years
  • Pregnancy
  • Primary hepatic malignancy (hepatocellular carcinoma, cholangiocarcinoma) with portal invasion and/or extrahepatic spread

Trial design

156 participants in 1 patient group

cACLD
Description:
Patients with compensated advanced chronic liver disease (cACLD) regardless of etiology
Treatment:
Diagnostic Test: hepatomiR

Trial contacts and locations

1

Loading...

Central trial contact

Lukas Erhart, Mag. Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems